This site is intended for health professionals only

Thursday 22 August 2019
Share |

Latest News

Dupilumab reaches primary and secondary endpoints in paediatric trial

Thursday 8th August 2019
A pivotal Phase III trial evaluating Dupixent® (dupilumab) in severe atopic dermatitis in children has met its primary and secondary endpoints. 
The topline data show that for children with severe atopic dermatitis (covering nearly 60% of their skin surface on average), adding Dupixent to standard-of-care topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching and health-...
Thu, 6 Jun 2019
Psychiatric comorbidities, including intellectual disability and depression, are common for adults who have epilepsy
Thu, 6 Jun 2019
The risk of pneumonia was highest among those using strong opioids, such as oxycodone or fentanyl, but the risk was also increased among those using buprenorphine, tramadol or codeine
Thu, 6 Jun 2019
The results support a robust set of existing data demonstrating the sustained efficacy, safety, and tolerability of continuous ibrutinib treatment in patients with CLL
Thu, 6 Jun 2019
In the Phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps with inadequate response to intranasal corticosteroids
Sun, 2 Jun 2019
The evidence-based recommendations for the prevention and management of adult antiphospholipid syndrome are designed to help guide practice – and improve quality of care and patient outcomes
Fri, 31 May 2019
A Federation called Sjögren Europe has been created by the national patient associations of ten European countries
Thu, 30 May 2019
QUARTZ is the first completed study of the Phase III PLATINUM clinical development program which evaluates both QMF149 and QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate)